Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 60 of 1,261
  1. US 12233051

    Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  2. US 12233166

    Extended release compositions comprising pyridostigmine

    Amneal Complex Products Research LLC Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  3. US 12233106

    C-type natriuretic peptide variants to treat skeletal dysplasia in children

    BIOMARIN PHARMACEUTICAL INC. Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  4. US 12234300

    Conjugated hepcidin mimetics

    Protagonist Therapeutics, Inc. Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  5. US 12234295

    Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof

    AUTOLUS LIMITED Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  6. US 12233129

    Methods and compositions for the treatment of cancer

    SOUTH DAKOTA BOARD OF REGENTS Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  7. US 12234236

    GLP-1R agonist and therapeutic method thereof

    Ascletis Pharma (China) Co., Limited Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  8. US 12233135

    Therapeutic constructs for treating cancer

    PRECISION MOLECULAR INC. Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  9. US 12233103

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  10. US 12233087

    Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions

    The United States Government represented byt The United States Department of Veterans Affairs Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  11. US 12232492

    Disinfection of bacteriophages products using supercritical carbon dioxide

    PRECISIONBIOTIX TECHNOLOGIES INC. Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  12. US 12233080

    Lipotechoic acid for immune modulation

    Northwestern University Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  13. US 12233124

    Recombinant metapneumovirus f proteins and their use

    The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  14. US 12234461

    Targeted non-viral DNA insertions

    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  15. US 12234474

    Method to prevent the myelin abnormalites associated with arginase deficiency

    The Regents of the University of California Β· Granted Feb 25, 2025 Β· Expires Feb 20, 2045

    granted
  16. WO 2025038863

    DÉRIVÉS D'INDOLE ET DE PYRROLOYPYRIDINE UTILISÉS EN TANT QUE MODULATEURS DE GPR17

    BIOGEN MA INC [US] Β· Granted Feb 20, 2025 Β· Expires Feb 15, 2045

    granted
  17. US 2025059280

    METHODS OF TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE

    ABBVIE INC [US] Β· Granted Feb 20, 2025 Β· Expires Feb 15, 2045

    granted
  18. US 2025057837

    Methods for Treating HCV

    ABBVIE INC [US] Β· Granted Feb 20, 2025 Β· Expires Feb 15, 2045

    granted
  19. US 12227584

    Multivalent and multispecific OX40-binding fusion proteins

    Inhibrx Biosciences, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  20. US 12228582

    Method and apparatus for testing near infrared-photoimmunotherapy treatment

    The United States of America as Represented By The Secretary of the Department of Health and Human Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  21. US 12227740

    CBLB endonuclease variants, compositions, and methods of use

    REGENERON PHARMACEUTICALS, INC. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  22. US 12228572

    Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-infected cells

    The First Hospital of China Medical University Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  23. US 12226610

    Treatment of pain associated with total knee arthroplasty with sustained-release liposomal anesthetic compositions

    Pacira Pharmaceuticals, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted
  24. US 12227508

    TGF-Ξ² inhibitors

    Rigel Pharmaceuticals, Inc. Β· Granted Feb 18, 2025 Β· Expires Feb 13, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.